Skip to main content

Monte Rosa Therapeutics, Inc. (GLUE)

NASDAQ: GLUE · Delayed Price · USD
30.73 -2.38 (-7.19%)
Sep 17, 2021 4:00 PM EDT - Market closed
Market Cap1.43B
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out5.07M
EPS (ttm)-22.82
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,076,126
Open33.05
Previous Close33.11
Day's Range30.53 - 34.26
52-Week Range18.01 - 45.56
Betan/a
Analystsn/a
Price Target39.33 (+28.0%)
Est. Earnings DateNov 11, 2021

About GLUE

Monte Rosa Therapeutics is a biopharmaceutical company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically-relevant proteins. We have developed a proprietary protein degradation platform, called QuEEN, that enables us to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates that are designed to eliminate therapeutically-relevant proteins in a highly selective manner. We have utilized our QuEEN, platform to design ...

IndustryBiotechnology
IPO DateJun 24, 2021
CEOMarkus Warmuth, M.D.
Employees83
Stock ExchangeNASDAQ
Ticker SymbolGLUE
Full Company Profile

Financial Performance

Financial Statements

News

Monte Rosa Therapeutics Announces Addition to Russell 2000® and Russell 3000® Indexes

BOSTON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that it will be adde...

1 week ago - GlobeNewsWire

Monte Rosa Therapeutics to Participate in Morgan Stanley 19th Annual Global Healthcare Conference

BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that Markus Warmuth,...

1 week ago - GlobeNewsWire

Monte Rosa Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress

– Completed upsized $255.6 million IPO; cash runway extended into late 2024

1 month ago - GlobeNewsWire

Monte Rosa Therapeutics Announces Pricing of Initial Public Offering

BOSTON, June 23, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body's ...

2 months ago - GlobeNewsWire

Monte Rosa Therapeutics IPO Registration Document (S-1)

Monte Rosa Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC